EP08.02-126 The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping

Abstract

MET exon 14 (METex14) skipping activates oncogenic MET signaling in 3-4% of patients with non-small cell lung cancer (NSCLC). The low frequency of this alteration has influenced the investigation of MET inhibitors, often leading to an open-label, single-arm trial design, in order to maximize the number of patients receiving these compounds. One example is the global Phase II VISION single-arm study of the oral, highly selective MET inhibitor tepotinib in patients with METex14 skipping NSCLC, in which tepotinib demonstrated robust and durable activity with an objective response rate of 49.1% (data cut off: Feb 1, 2021).